Express Healthcare
Home  »  News  »  J Mitra and Company launches COVID-19 Microlisa Elisa Test kit

J Mitra and Company launches COVID-19 Microlisa Elisa Test kit

0 165
Read Article

All necessary approvals from the Indian Council of Medical Research (ICMR) and the Drugs Controller General of India (DCGI) have been received, the company said in a statement

J Mitra and Company has launched the COVID-19 Ag Microlisa Elisa Test kit (Elisa antigen test) for the Indian market. The test kit will provide an impetus to India’s fight against COVID-19 by significantly bringing down the overall cost of testing. It will also offer better time efficiencies by reducing the turn-around time between testing and results to just two hours, a statement said.

It also said that the principle of the test kit is Sandwich Elisa. Any open Elisa kit reader available in the market can read the results. Open-system will result in efficient testing even in the remotest corners of the country. The country already has thousands of Elisa readers with laboratories across the country.

It is the first kit designed for the in-vitro qualitative detection of COVID-19 nucleocapsid antigen in nasal and oropharyngeal swabs and sample diluent. The Elisa antigen COVID-19 test offers high sensitivity and specificity, and accuracy equivalent to RT-PCR tests at costs that are comparable to rapid tests. All necessary approvals from the Indian Council of Medical Research (ICMR) and the Drugs Controller General of India (DCGI) have been received, notified the statement.

Speaking about the launch, Lalit Mahajan, Chairman, J Mitra & Co, said, “The Elisa antigen test is our 10th R&D based product in the fight against COVID-19. We are committed to the masses and will strive to help in the eradication of the disease.”

In addition to it, while talking about practical usages of the EAT, Jatin Mahajan, Managing Director, J Mitra & Co, said, “The Elisa antigen test will help in management and mitigation of risks through quicker and reliable results – positive patients can be quickly isolated. For the masses, this test will minimise uncertainty and confusion due to prolonged delays in test results – to decide whether it is safe to interact or isolate and quarantine. We hope to majorly transform the testing and detection scenario with this path-breaking product.”

Leave A Reply

Your email address will not be published.

Attend an exclusive webinar to know more about biomarkers in diagnosis & therapy management of heart failure.
Register Now
close-image
 Introducing Smart Autoinjector: Changing the paradigm of usability, cost & size
Know More?
close-image
Are you looking for ICP-MS which can increase productivity and remove time trap from your analysis?
Know More
close-image